DadFinStart your free week
DadFin › Stocks › Healthcare › UTMD

Utah Medical Products, Inc. (UTMD) stock score

Healthcare · Medical Instruments & Supplies · United States

$74.54 ▲ +0.89% today

76.5
Dad Score, out of 100
good

Utah Medical Products, Inc. (UTMD) is a Medical Instruments & Supplies company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 76.5 out of 100 on the Dad Score, a good reading that places the business ahead of 76% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #210 of 974. Its strongest axes are valuation, quality and price action; its weakest are growth and risk.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Above average
Growth
Weak
Price action
Strong
Risk
Below average
Conviction
Below average
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)22.6×
P/E (forward)0.0×
Dividend yield1.66%
Return on capital11.8%
Operating margin36.9%
Revenue growth (YoY)-5.8%
FCF yield9.6%
Net debt / EBITDA-6.08×
Piotroski F-Score5 / 9
52-week change+20.5%
Market cap$235M
Next earningsOct 22, 2026

What subscribers see on UTMD

Start your free weekSubscriber? Open the full research →

Medical Instruments & Supplies peers

StockCompanyDad ScoreBandMarket cap
ISRGIntuitive Surgical, Inc.87.0strong$140.4B
BDXBecton, Dickinson and Company69.8middling$48.2B
MDLNMedline Inc.98.2strong$47.9B
ALCAlcon Inc.64.6middling$30.8B
RMDResMed Inc.94.3strong$30.8B
WSTWest Pharmaceutical Services, Inc.90.1strong$25.7B
SOLVSolventum Corporation71.9good$15.0B
BAXBaxter International Inc.40.5middling$12.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.